Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Hypertrophic cardiomyopathy (HC) is an inherited heart disease characterized by left ventricular (LV) remodeling. The present study was conducted to investigate the association of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) levels with LV remodeling on magnetic resonance imaging and procollagen formation in 17 healthy controls and 24 patients with nonobstructive HC attributable to an identical Asp175Asn (aspartic acid to asparagine at codon 175) mutation in the alpha-tropomyosin gene. None of the patients had history of decompensated heart failure, and all patients had normal LV ejection fraction. Patients with HC had higher NT-pro-BNP levels compared with controls (median 60 pmol/L, range <40 to 359, vs <40 pmol/L; p <0.001), but 9 patients with HC had normal NT-pro-BNP levels (<40 pmol/L). In patients with HC, levels of NT-pro-BNP were correlated significantly with LV end-systolic volume index (r = 0.50, p <0.05), LV mass index (r = 0.47, p <0.05), proportion of hypokinetic segments (r = 0.50, p <0.05), and levels of serum aminoterminal propeptide of type III procollagen (r = 0.52, p <0.01). When patients with HC were divided into 3 groups on the basis of their NT-pro-BNP levels, there were statistically significant linear associations of LV end-systolic volume (test for linearity p = 0.034), LV mass index (p = 0.009), proportion of hypokinetic segments (p = 0.016), and levels of serum aminoterminal propeptide of type III procollagen (p = 0.020) with NT-pro-BNP levels over the 3 groups, suggesting a tight relation between LV remodeling and levels of NT-pro-BNP. In conclusion, in patients with nonobstructive HC attributable to an Asp175Asn mutation in the alpha-tropomyosin gene, elevated NT-pro-BNP levels are associated with incipient LV remodeling, suggesting that NT-pro-BNP could be used to diagnose insidious unfavorable LV remodeling in HC.
...
PMID:Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. 1839 56

Biomarkers should have high sensitivity, specificity, reproducibility, be cost-effective, and provide incremental predictive or diagnostic utility over standard risk factors or tests. Despite numerous studies investigating biomarkers in heart failure (HF), there are only a few that predict HF in hypertensive patients. This article summarizes data from numerous studies concerning possible biomarkers of HF in hypertensive patients such as: serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP-1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP) and N-terminal propeptide of type III procollagen (PIIINP), metalloproteinases (MMPs), B-type natriuretic peptide (BNP) and its derivatives, glycoprotein CA125 and cystatin C. Early detection of patients of increased risk of hypertensive heart disease may result in early implementation of effective preventive strategies. Therefore, there is need to identify newer biomarkers, if they can improve risk prediction, identifying patients, in which earlier or more aggressive intervention will improve clinical outcomes.
...
PMID:An update on biomarkers of heart failure in hypertensive patients. 2282 89

Relationship between changes of electrocardiogram (ECG) indexes in chronic heart failure (CHF) with arrhythmia and serum type III procollagen amino-terminal peptide (PIIINP) and brain natriuretic peptide (BNP) were evaluated. From December 2017 to December 2018, 101 patients with heart failure (HF) were collected. Among them, 48 patients with HF and slow arrhythmia were in group A, and 53 cases of HF with non-slow arrhythmia were sin group B, including 33 males and 20 females. BNP was detected by chemiluminescence and PIIINP was detected by immunoassay. The changes of ECG indexes in the two groups, the correlation between serum PIIINP and BNP and NYHA classification of cardiac function, and the correlation between ECG indexes and PIIINP and BNP were detected. ROC curve analysis of BNP and PIIINP in the diagnosis of slow HF was carried out. Serum PIIINP and BNP in group A were significantly higher than those in group B (P<0.05). The levels of PIIINP and BNP in serum of NYHA patients with different cardiac functions, and those in serum of patients with class III were significantly higher than those of group II (P<0.05), while significantly lower than those of group IV (P<0.05). The heart rate and Q-T interval in group A were significantly higher than those in group B (P<0.05). The P-R interval and QES wave group in group A were significantly lower than those in group B (P<0.05). BNP had a positive correlation with Hr and G-T, and was negatively correlated with P-R and QRS; PIIINP was positively correlated with Hr and G-T, and had a negative correlation with P-R, QRS and BNP; PIIINP had positive correlation with NYHA; ECG indexes were correlated with BNP and PIIINP, and had diagnostic value for CHF. Using ECG indexes to predict BNP and PIIINP levels was conducive to the diagnosis of CHF.
...
PMID:Relationship between changes of electrocardiogram indexes in chronic heart failure with arrhythmia and serum PIIINP and BNP. 3189 1